Feature | October 11, 2013

SCAI Proposes New Definition for Heart Attack After Angioplasty or Bypass Surgery

Definition focuses on clinically relevant criteria with strong links to outcomes

cath lab cardiovascular surgery clinical trial/study scai heart attack

October 11, 2013 —The Society for Cardiovascular Angiography and Interventions (SCAI) assembled  a panel that has proposed new criteria for identifying patients who experience a heart attack after coronary angioplasty or bypass surgery. The new criteria and their implications for patient care are detailed in an expert consensus document e-published in Catheterization and Cardiovascular Interventions (CCI) and the Journal of the American College of Cardiology (JACC).

By focusing specifically on post-procedure heart attacks that have the potential to influence a patient’s clinical outcomes, the new definition may improve not only patient care but also the way heart procedures are evaluated for quality and effectiveness.

“This definition of heart attack would better identify those patients with true complications after angioplasty or bypass surgery who require urgent action, better reflect the quality of these procedures and inform future research designed to identify the best preventive strategies,” said Issam D. Moussa, M.D., fellow, Society for Cardiovascular Aniography (FSCAI), chair, division of cardiovascular diseases at Mayo Clinic in Jacksonville, Fla., and professor of medicine, Mayo Clinic College of Medicine.

The new criteria, developed by physicians representing both interventional cardiology and cardiac surgery, differ from the existing criteria in several ways. Both diagnose a heart attack primarily by detecting a protein in the blood that is released when the heart muscle is damaged. However, the definitions differ by which protein is the preferred marker, how high the protein level must rise to signal a heart attack and under what circumstances additional evidence from an electrocardiogram (ECG), imaging test or symptoms is needed to confirm the diagnosis.

The existing definition calls for a relatively small increase in cardiac troponin (to five times the normal level) plus confirmation by an ECG, an imaging test or symptoms. In most cases, the new definition calls for a large increase in the blood level of CK-MB (to at least 10 times the normal level). If CK-MB is not available, the new definition calls for a troponin level that is 70 times normal. If the ECG tracing provides strong evidence of a heart attack, then the new definition allows for blood levels of CK-MB and troponin that are five times and 35 times normal, respectively.

The disparities between the two definitions highlight critical differences in their diagnostic goals. The existing definition, by relying on small protein leaks from the heart muscle, can detect even minimal heart damage. However, this information does not necessarily help doctors determine a patient’s prognosis because minimal heart damage is unlikely to influence short- and long-term survival, the likelihood of having another heart attack and other important clinical outcomes. In contrast, the new definition focuses on detecting prognostically meaningful heart attacks that can be expected to affect a patient’s heart function, well-being and future health.

“If you tell a patient, ‘You have had a heart attack,’ it should mean something about clinical outcomes, not microscopic injury to the heart muscle,” said Moussa. “This diagnosis has important implications. It could lead to longer hospital stays, more blood tests and repeat imaging procedures. It could even affect a patient’s job.”

 The new definition offers additional advantages, including the following:

  • Focusing on the link between a large rise in CK-MB levels and poor long-term outcomes after angioplasty or bypass surgery, an association that has been validated in numerous clinical studies. Although troponin is the preferred protein marker to use in diagnosing a spontaneous heart attack, its role in diagnosing prognostically important heart attacks after stenting or bypass surgery has not been well validated, particularly at the levels specified in the existing definition.
  • Bringing uniformity to the criteria used to diagnose heart attack after PCI and bypass surgery. The existing definition uses different standards for the two types of procedures.
  • Focusing on clinically relevant outcomes, allowing for more meaningful assessment of physician and program quality.
  • Focusing on clinically relevant outcomes, which would also aid clinical research by enabling better comparison between various methods of treating coronary artery disease.

“This is not about semantics by any means,” said Moussa. “How we define a heart attack after angioplasty or bypass surgery can have a significant impact on patient perception, healthcare resource utilization and how we measure the quality of these procedures.”

 For more information: www.scai.org

Related Content

LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
St. Jude Medical, HeartMate 3 LVAS, MOMENTUM 3 IDE study results, AHA Scientific Sessions 2016
News | Ventricular Assist Devices (VAD)| December 08, 2016
St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial...
Sponsored Content | Videos | Angiography| December 07, 2016
Shimadzu's latest generation interventional lab angiography imaging system, the Trinias, enables advanced imaging cap
Lotus Edge valve
News | Heart Valve Technology| December 07, 2016
December 7, 2016 — Boston Scientific announced a definitive agreement to acquire certain manufacturing assets and cap
Impella CP, Abiomed
News | Hemodynamic Support Devices| December 07, 2016
December 7, 2016 — Abiomed Inc. announced it has expanded its U.S.
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
Siemens Healthineers, PURE Platform, angiography, EVAR, CTO, RSNA 2016
News | Angiography| December 07, 2016
December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging| December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Overlay Init